AU2008350273B2 - HIV-1 envelope glycoprotein oligomer and methods of use - Google Patents

HIV-1 envelope glycoprotein oligomer and methods of use Download PDF

Info

Publication number
AU2008350273B2
AU2008350273B2 AU2008350273A AU2008350273A AU2008350273B2 AU 2008350273 B2 AU2008350273 B2 AU 2008350273B2 AU 2008350273 A AU2008350273 A AU 2008350273A AU 2008350273 A AU2008350273 A AU 2008350273A AU 2008350273 B2 AU2008350273 B2 AU 2008350273B2
Authority
AU
Australia
Prior art keywords
polypeptide
oligomer
fusion polypeptide
fusion
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008350273A
Other languages
English (en)
Other versions
AU2008350273A1 (en
Inventor
Christopher Broder
Gerald Quinnan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Publication of AU2008350273A1 publication Critical patent/AU2008350273A1/en
Application granted granted Critical
Publication of AU2008350273B2 publication Critical patent/AU2008350273B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2008350273A 2007-11-12 2008-11-12 HIV-1 envelope glycoprotein oligomer and methods of use Ceased AU2008350273B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98728707P 2007-11-12 2007-11-12
US60/987,287 2007-11-12
PCT/US2008/083190 WO2009102357A2 (en) 2007-11-12 2008-11-12 Hiv-1 envelope glycoprotein oligomer and methods of use

Publications (2)

Publication Number Publication Date
AU2008350273A1 AU2008350273A1 (en) 2009-08-20
AU2008350273B2 true AU2008350273B2 (en) 2014-04-10

Family

ID=40957413

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008350273A Ceased AU2008350273B2 (en) 2007-11-12 2008-11-12 HIV-1 envelope glycoprotein oligomer and methods of use

Country Status (6)

Country Link
US (1) US8597658B2 (https=)
EP (1) EP2235065A4 (https=)
JP (1) JP2011502521A (https=)
AU (1) AU2008350273B2 (https=)
CA (1) CA2705373A1 (https=)
WO (1) WO2009102357A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015001390B1 (pt) * 2012-07-26 2024-04-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc Proteína de fusão, ácido nucleico isolado e uso de uma composição de vacina
IL299962A (en) * 2016-05-02 2023-03-01 Scripps Research Inst Compositions and methods related to HIV-1 immunogens
KR20230019227A (ko) * 2017-11-17 2023-02-07 그리폴스 다이어그노스틱 솔루션즈 인크. 신규한 포유동물 발현 인간 면역결핍 바이러스 외피 단백질 항원

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019958A2 (en) * 1999-09-17 2001-03-22 Dana-Farber Cancer Institute, Inc. Stabilized soluble glycoprotein trimers
WO2006026508A2 (en) * 2004-08-27 2006-03-09 The Henry M. Jackson Foundation Modified hiv-1 envelope proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292646A (en) * 1991-02-06 1994-03-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US6039957A (en) * 1993-12-10 2000-03-21 United States Of America, As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
DE69941051D1 (de) * 1998-08-04 2009-08-13 Jackson H M Found Military Med Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier
WO2003077838A2 (en) * 2002-03-05 2003-09-25 National Institutes Of Health Office Of Technology Transfer Hiv-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and immunogens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019958A2 (en) * 1999-09-17 2001-03-22 Dana-Farber Cancer Institute, Inc. Stabilized soluble glycoprotein trimers
WO2006026508A2 (en) * 2004-08-27 2006-03-09 The Henry M. Jackson Foundation Modified hiv-1 envelope proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
QUINNAN G. V. et al, "Expression and characterisation of HIV type 1 envelope protein associated with a broadly reactive neutralising antibody response", AIDS research and human retroviruses, 1999, vol 15, no 6, pages 561-570 *
YANG X, et al, "Highly stable trimmers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin", Journal of Virology, 2002, vol 76, no 9, pages 4634-4642 *

Also Published As

Publication number Publication date
JP2011502521A (ja) 2011-01-27
WO2009102357A2 (en) 2009-08-20
AU2008350273A1 (en) 2009-08-20
EP2235065A4 (en) 2011-09-28
CA2705373A1 (en) 2009-08-20
US8597658B2 (en) 2013-12-03
US20100316661A1 (en) 2010-12-16
EP2235065A2 (en) 2010-10-06
WO2009102357A3 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
JP6735269B2 (ja) インフルエンザウイルスワクチンおよびその使用
ES2635080T3 (es) Vacunas contra el cáncer dirigidas a células presentadoras de antígenos
US20190322731A1 (en) Molecular Complex for Targeting Antigens Towards Cells Comprising Antigens and Uses Thereof for Vaccination
JP7094103B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP6643981B2 (ja) インフルエンザウイルスワクチンおよびその使用
AU2018202997A1 (en) DNA antibody constructs and method of using same
KR20180131584A (ko) 안정화된 용해성 융합-전 rsv f 단백질
US20210009640A1 (en) Compositions comprising hiv envelopes to induce hiv-1 antibodies
EP2877205A2 (en) Multimeric fusion protein vaccine and immunotherapeutic
US20210379178A1 (en) Compositions comprising hiv envelopes to induce hiv-1 antibodies
JP2023156458A (ja) 新規足場ｈｉｖ－１ワクチン免疫原
US20190031721A1 (en) Soluble Forms of Hendra and Nipah Virus F Glycoprotein and Uses Thereof
AU2008350273B2 (en) HIV-1 envelope glycoprotein oligomer and methods of use
CA2914555A1 (en) Single domain antibody display
JP2022553258A (ja) インフルエンザウイルスワクチン及びその使用
US20240307524A1 (en) Coronavirus vaccines
US8475799B2 (en) HIV-1 GP41 neutralization domain and use thereof
AU2013276968A1 (en) Soluble Forms of Hendra and Nipah Virus F Glycoprotein and Uses Thereof
JP4549666B2 (ja) 抗体の製造方法
EP3104884B1 (en) A new non-hiv vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against hiv infection
JP2020162607A (ja) インフルエンザウイルスワクチンおよびその使用
WO2022161598A1 (en) Antibodies broadly targeting coronaviruses and uses thereof
KR20120095979A (ko) 강화된 말라리아 ｍｓｐ-1 서브유닛 백신
AU2016222452A1 (en) Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired